Li Ning

Junshi Biosciences is a leading innovation-driven biopharmaceutical company based in China, specializing in the discovery, development, and commercialization of novel therapies. The company's flagship product, Toripalimab (Loqtorzi), was the first domestic anti-PD-1 monoclonal antibody approved in China and has since received FDA approval in the United States for nasopharyngeal carcinoma. Junshi's extensive pipeline focuses on oncology, metabolic diseases, inflammation, and autoimmune disorders, utilizing advanced antibody and small molecule platforms. With a strong emphasis on global expansion, the company has established numerous partnerships with international pharmaceutical firms, including Eli Lilly and Coherus BioSciences, to bring its innovative treatments to patients worldwide.